FibroBiologics closes $3M public offering of common stock and warrants at $1.32/unit

FibroBiologics, Inc.

Offering of 2,272,728 shares (or pre-funded warrants) plus warrants, combined price $1.32/unit; net proceeds ~$2.5M after fees.
Warrants exercise price $1.32, exercisable only after stockholder approval; if fully cash-exercised, additional $3M proceeds possible.
Pre-funded warrants exercise price $0.00001, no expiration; beneficial ownership cap 9.99%.
Placement agent H.C. Wainwright received 7.0% cash fee, 1.0% management fee, and 159,091 placement agent warrants at $1.65.
Lock-up: insiders 30 days; company restricted from further equity issuance for 30 days and no variable-rate transactions for one year.

item 1.01 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

FibroBiologics, Inc. entered into Purchase Agreement with certain investors (effective 2026-03-31).

Action: entry
Agreement: equity purchase
Counterparty: certain investors
Effective: 2026-03-31

Exact text from the filing

certain of the investors purchased their Shares and Pre-Funded Warrants, together with the accompanying Warrants, pursuant to a securities purchase agreement, dated March 31, 2026, by and among the Company and such investors (the “Purchase Agreement”).

View on SEC.gov

301 material agreements filed in the last 30 days. Browse all material agreements →

FibroBiologics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-140044

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.